Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population

Table 1

Baseline demographic data.

			Total
Age	223		53.7 (51.8, 55.6)
Gender	223	F	184 (82.5%)
		M	39 (17.5%)
Ethnicity	213	Māori	71 (31.9%)
		NMāori	142 (63.6%)
Diagnosis	223	Graves’s	142 (63.6%)
		TMNG	75 (33.6%)
		STA	6 (3.7%)
Median weight (kg)	208		74.6 (52.2, 118.8)
Ophthalmopathy	140	Nil	103 (73.57%)
		Mild	26 (18.57%)
		Mod.	7 (5.00%)
		Sev.	4 (2.86%)
T4 at presentation	210		29 (12, 65.4)
Pretreatment ATD	223		184 (86.4%)
Length of ATD (wks)	193		49 (13, 439)
Posttreatment ATD	192		74 (38.54%)
Length of FU (wks)	223		913 (432, 1466)

ATD: antithyroid medication; F: female; M: male; NMāori: non-Māori; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; Mod.: moderate eye disease; Sev.: severe eye disease.
Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).